DiscoverThe Cannabis Conversation | Medical Cannabis | CBD | Hemp
The Cannabis Conversation | Medical Cannabis | CBD | Hemp
Claim Ownership

The Cannabis Conversation | Medical Cannabis | CBD | Hemp

Author: Anuj Desai

Subscribed: 91Played: 2,491


The cannabis industry is gaining traction across the world, as new medical discoveries, and multi-billion dollar businesses are grabbing the headlines on a regular basis. Experts predict the worldwide industry could be worth in excess of $300bn within 10 years, with Europe forming the biggest market within that, so there's plenty to get excited about. I want to find out more about what's happening, and I'm bringing you along for the ride. Join me - Anuj Desai - as I speak to a wide variety of guests who are helping to shape this nascent sector. Having interviewed over 100 guests, including patients, lawyers, doctors, scientists, entrepreneurs, investors and many more, we discover how, and why, this much maligned and misunderstood plant is giving birth to a huge global business.
145 Episodes
In our latest episode, we’re joined by Paul Steckler, Managing Director for Canopy Growth International. We discuss the challenges of fitting cannabis production into a traditional pharmaceutical medical framework, along with some of the biggest UK-centric, economic and market challenges associated with operating within this space.📚 VIEW SHOW NOTES AND EXTRAS: Paul StecklerPaul Steckler is the Managing Director for Canopy Growth in international markets including Europe and APAC. Paul is a seasoned pharmaceutical executive with over 20 years’ experience in commercial roles, having worked in both large and small pharmaceutical companies.In his 15 years as Commercial Director at Pfizer, Paul successfully grew specialty brands from pre-launch to loss of exclusivity. Additionally, Paul oversaw a successful IPO while Chief Commercial Officer at Shield Therapeutics Plc., a London listed AIM specialty research-based pharmaceutical company, while simultaneously overseeing leading global commercial operations. Paul is also an eco-conscious vegetarian, avid cyclist and football coach.QuotablesThe industry is quite new, and it's exciting. It's entrepreneurial. Everyone is kind of learning as they go alongResourcesCanopy Growth’s Website: Paul on LinkedIn: on LinkedIn:
In our latest episode, we’re joined by Peter Sigetty - COO of Valcon Medical - Danish medical cannabis contract manufacturers of Pharmaceutical-Grade Cannabis Extracts.Within the context of the European medical cannabis supply and value chain, we explore the dynamics of vertical integration and how sector specialisation can help businesses navigate the complexities of the European market.📚 VIEW SHOW NOTES AND EXTRAS: Peter Emil SigettyPeter Emil Sigetty is co-founder and COO of Valcon Medical. Peter holds a M.S.c in Economics & Business Administration and has a professional background in finance and accounting. Peter has worked in the medical cannabis industry since it’s inception in Denmark in 2018 where Valcon Medical was founded. QuotablesEurope cannot be treated as a whole when it comes to medical cannabisI believe as the scope and product variation and the patient base grows, [medical cannabis]  will be more commonly recognized [by doctors]. But there will always be reluctance.ResourcesWebsite: Peter on LinkedIn: Valcon Medical on LinkedIn:
This week, we’re bringing you another episode recorded in Odense, Denmark. On this show, we’re joined by Mariolla Schroll, Public Relations Officer at Schroll Medical - family owned medical cannabis producer.We examine the cultivation of medical cannabis, including desirable genetic characteristics, common breeding methods, and the steps needed to achieve GMP compliance as a Danish producer.About Schroll MedicalSchroll Medical, which originates from Schroll Flowers, is among the leading medical cannabis producers in Denmark. The company operates an extensive breeding program and continues to innovate within the sector to meet patient needs. Schroll Medical ApS is the only producer of medical cannabis that is both Danish-led and Danish-owned and licensed to cultivate and sell medical cannabis.  Through its parent company Schroll Management ApS, Schroll Medical ApS has access to extensive experience with plant breeding and the establishment of efficient plant production. Quotables‘What is a strain? A specific cultivar? No, a strain is a specific breeding direction’ResourcesSchroll Medical’s Website: Schroll Medical on LinkedIn: with Mariolla on LinkedIn:
Last month, the recently elected coalition government in Germany announced their initial plans to legalise cannabis for recreational use.There has understandably been a lot of excitement about this news, so on this week’s episode Alfredo Pascual from Seed Innovations, Franziska Katterbach from Khiron Life Sciences, and Tom Blickman from Transnational Institute join me to discuss how the upcoming legislation may disrupt and revolutionise the recreational and medical markets within Germany and Europe on a wider scale.About Our GuestsAlfredo PascualVP of Investment Analysis, Seed Innovations Based in Germany, Alfredo is a prominent cannabis industry analyst who has been identifying opportunities and generating unique insights for businesses and investors in Europe and Latin America since 2016. He is currently VP of Investment Analysis of Seed Innovations Ltd (LON: SEED), the AIM quoted company investing in fast growing and industry leading businesses with a focus on the medical cannabis, health and wellness space. Before joining Seed Innovations, Alfredo worked as International Analyst at Marijuana Business Daily (MJBiz), the US-based business news and information resource, where he focused on covering how cannabis markets and investments were evolving internationally. Alfredo has an academic background in business and public policy.Connect with Alfredo on LinkedIn: BlickmanSenior Project Officer, Transnational InstituteTom Blickman (1957) is a Senior Project Officer at the Transnational Institute (TNI), based in Amsterdam. Since 1997, he has been working for TNI's Drugs Programme, specializing in international drug control policy and the UN conventions, drug markets, alternative development, money laundering and organised crime. More recently he is closely following cannabis regulation policies in Europe and elsewhere. Tom is a regular speaker at international policy conferences and advises on developments in the drugs field. He is co-editor of the TNI Drug Policy Briefing series.Connect with Tom on LinkedIn: KatterbachPresident, Khiron Life SciencesFranziska Katterbach is an accomplished business executive and legal expert (zugelassene Rechtsanwältin) who brings extensive experience working within Europe's emerging cannabis industry. After completing her legal studies at Universität Leipzig and Landgericht Darmstadt, Franziska joined the corporate law firm Dentons, where she was involved in high-profile deals in the cannabis sector across multiple jurisdictions. Franziska later served as Director of Legal for Canopy's European operations, before joining Khiron. With 8+ years of regulatory expertise and 4+ as business executive in the European emerging cannabis industry, Franziska has well rounded knowledge in the industry. Franziska is considered a pioneer of the medical cannabis market in Germany, working in the medical cannabis industry in Europe on executive level since the very beginning in 2016.Connect with Franziska on LinkedIn:
This week we welcome to the show Mike Simpson, Co-founder and CEO of Omura, technology and design company innovating within the cannabis inhalation market. We investigate the rise in popularity and benefits of heat-not-burn technology, how it compares to more traditional ways of ingesting cannabis, and how this innovation is revolutionising the cannabis and tobacco industries.About Mike SimpsonMike is a seasoned entrepreneur specializing in transformational technologies. Mike is one of the world’s leading experts in the field of heat-not-burn technology, having spent much of the past 15 years developing next generation products for British American Tobacco.Quotables‘It's interesting how the world's changing… the dominoes are toppling and the rate of change is accelerating’ResourcesConnect with Mike on LinkedIn:’s Website:
This week’s episode comes to you from Odense in Denmark, where we’re joined by Connor Jensen Murphy and Justin Ihnken from Danish full service cannabis testing and analysis lab, QNTM Labs.We examine the importance of continuity, standardisation, and frameworks with the context of cannabis laboratory testing, and how QNTM Labs are helping to bring pharmaceutical testing standards to the European medical cannabis industry.About QNTM LabsQNTM Labs is an advanced analytical laboratory providing research, development, and regulatory compliance services for pharmaceutical companies.Founded in 2020 and headquartered in Odense, Denmark, QNTM is dedicated to developing innovative analytical methods while maintaining the highest quality levels to forge new industry standards.As global sentiment is increasingly focused on quality data, QNTM Labs is determined to improve transparency and access to robust scientific analysis, working hand-in-hand with global cultivators, API manufacturers, and pharmaceutical industry stakeholders through analytical testing, contract research and clinical trials support.About Justin IhnkenJustin Ihnken is the Chief Executive Officer and Co-founder of QNTM Labs, a state-of-the-art GMP-certified laboratory dedicated to supporting plant-based pharmaceuticals. Outside of QNTM Labs, Justin also currently sits on the Board of Directors for the American Club of Copenhagen.Prior to founding QNTM Labs, Justin worked in Copenhagen for Danish global shipping conglomerate, A.P. Møller-Mærsk, where he was responsible for interest rate portfolio management and derivative trading, as a part of the company’s global treasury team. Before moving to Denmark in 2018, Justin built his professional career in institutional banking in New York City, within fixed income trading and interest rates.  Justin completed his education at Seton Hall University’s Stillman School of Business where he studied Mathematical Finance. About Connor Jensen MurphyConnor Jensen Murphy co-founded QNTM Labs in March 2020 and is currently the company’s Chief Operating Officer.  Connor has spent his career advising middle-market and founder-owned companies in corporate restructuring and M&A transactions.Prior to starting QNTM, Connor was a VP on EY’s Investment Banking team in Copenhagen focused on M&A transactions. Before moving to Copenhagen, he was based in San Francisco, California and also worked with EY’s Investment Banking group. Connor holds a B.A. from Colgate University where he studied Environmental Economics.ResourcesFollow QNTM Labs on LinkedIn: Labs Website: with Connor on LinkedIn: with Justin on LinkedIn:
On this week's episode, we’re joined by Tony Reeves, European Industrial Hemp Association (EIHA) board member, and CBD Consultant, working with regulators, the UK government and a variety of brands.We investigate changing consumer behaviours towards CBD, the latest drug delivery innovations within the sector, and the adoption of CBD within consumer packaged goods.About Tony ReevesTony is a board director & UK representative of the European Industrial Hemp Association (EIHA); the only pan-European hemp trades association ( Since 2016 he has been representing the industry to regulators (MHRA, Home Office, FSA, HPRA, FSAI) and contributing to presentations at the European level on various matters including novel food regulations, CBD and THC levels in food, food supplements, beverages and cosmetics. He is closely engaged with numerous stakeholders in the cannabis industry across multiple geographies encompassing manufactures, brand owners, retailers and investors. He is a member of the UKAS-led ‘CBD Food Product Approval Expert Group,’ the Food & Drink Federation’s (FDF) ‘CBD Working Group and a consultant to major organisations in North America and Europe including THG.Tony was European Managing Director of what became Aurora Hemp and former Marketing Director of Leatherhead Food Research Association; providing consulting services to the global food & beverage sectors. In a later role, he led the development and launch of a new vegetarian product range securing substantial listings within both health food and general store chains. Initially, he worked within the UK Government's scientific services before leaving to establish his own specialist analytical laboratory business; achieving key supplier status with most of the UK's major multiples. Tony holds an MBA from Warwick Business School.Quotables‘The more I learned, the more I was trapped in this black hole called hemp because it's amazing stuff’ 03:36‘This industry just keeps on giving’ 19:43ResourcesJoin Tony on LinkedIn: The European Industrial Hemp Organisation’s Website: Tony’s recent article for The Grocer titled ‘The UK has the potential to become a leading player in the CBD sector’:  
On this week's episode, we welcome Bek Muslimov & Nikolay Tretiyakov, Co-Founders of Leafy Tunnel - early stage VC firm investing in psychedelics and cannabis to combat mental health and pain disorders.We examine the European investment landscape within the psychedelic and cannabis sector, looking into the types of investors and funds operational within this space, alongside how they have changed as the market begins to build momentum.→ View full show notes, summary, and access resources here: Nikolay TretiyakovNikolay is a Co-Founding Partner at Leafy Tunnel. Nikolay is an investor in ATAI Life Sciences (a biotech platform curing mental health disorders) and Iuvo Therapeutics (a European cannabis company).Prior to Leafy Tunnel, in 2013 Nikolay founded Blue Wire Capital, a multi-strategy investment firm investing in European venture funds, technology and life science companies.Nikolay holds a BA degree from the University of Wolverhampton and an MBA from the Russian Academy of National Economy.About Bek MuslimovBek is a Co-Founding Partner at Leafy Tunnel. For the past 7 years, he has been investing in European technology and life science companies. His recent investments include ATAI Life Sciences and Iuvo Therapeutics.Prior to Leafy Tunnel, Bek was the Investment Director at Blue Wire where he led investments in Monzo, Superawesome, Homehero, Ocean Harvest, and IhateironingBek is an MBA graduate of London Business School, has completed a medical neuroscience course at Duke University and holds a medical cannabis specialisation from the University of Colorado Boulder.ResourcesLeafy Tunnel’s Website: Bek on LinkedIn: Nikolay on LinkedIn: Leafy Tunnel on LinkedIn:
On this week's episode, we welcome back Tej Virk, CEO of Akanda Corp - integrated medical cannabis company with operations in Africa and the UK.We examine the importance of ESG investments within the cannabis world, the opportunities they can bring, and the challenges that exist in this area.About Tej Virk​​Tej Virk is the CEO and Director of Akanda, an international medical cannabis company, cultivating ethically sourced cannabis in Lesotho. He started his career in investment banking, spending 15 years with BMO Capital Markets, with his final year focusing heavily on the cannabis industry. He transacted on over 100 IPOs and follow-on capital raises, including companies such as Canopy Growth Corp. and Tilray, before joining Canopy Growth Corp. in 2019, as Managing Director of Europe where he drove the multinational expansion of Canopy's European operations.  Virk then joined Khiron Life Sciences as President of Europe where he established the company’s European medical and consumer packaged goods business from scratch.Virk has earned a reputation for industry leading innovation and successful execution in the global cannabis space, including overseeing multiple European pharmaceutical and consumer product launches, bleeding-edge regulatory work, accreditation of medical education platforms for health care providers, e-commerce rollouts, multiple sector M&As, establishing telemedicine partnerships, and setting up supply chains and distribution channels in every continent. Virk was a founding member and executive group stakeholder for Project Twenty21, the UK’s largest medical cannabis study. The study published the first real-world data collected on medical cannabis in the UK, with findings indicating that legally prescribed cannabis provides clinically significant improvements in the quality of life of patients living with numerous medical conditions.Quotables‘I like to make a positive impact on society. That was one of my reasons for leaving the banking industry to to join the cannabis industry’ 4:42ResourcesAkanda Corp’s Website: Akanda Corp on Instagram: Akanda Corp on Twitter: Tej on LinkedIn: Tej on Instagram: Tej on Twitter: 
On this week's episode, we welcome Yoko Miyashita (CEO) & Janessa Bailey (Culture Editor) from Leafly - the world’s largest cannabis information resource and technology company.We dig into the Seeds of Change report that Janessa wrote for Leafly, and discuss some of its findings around social equity in cannabis, including the impact of an unequal cannabis industry, how we are still battling the negative consequences of prohibition today, and how the cannabis industry can deliver transformative justice to those who need it most.Learn more about Janessa's Seeds of Change report here -→ View full show notes, summary, and access resources here: Yoko MiyashitaYoko Miyashita was appointed CEO of Leafly in August 2020 after serving as the company’s General Counsel since 2019. Yoko has spent her career serving mission-driven companies navigating complex global regulatory environments in order to bring meaningful and compelling products to market.An expert in policy and advocacy, as General Counsel, she led Leafly’s position on key regulatory, compliance and government affairs issues. She has focused on progressing Leafly’s reputation as a trusted and authoritative cannabis resource and leveraged an understanding of current cannabis regulations, and opportunities for change, to help scale Leafly’s product and sales strategy.Previously, Yoko spent 14 years at Getty Images, where she led the global legal team as SVP and general counsel. Prior to joining Getty Images, she practiced law with Perkins Coie LLP in Seattle. She holds a J.D. from the University of Washington School of Law and a B.A. from the University of California, Berkeley.About Janessa BaileyJanessa was born and raised in the Midwest, and serves as Leafly's current culture editor. She has a background in content, activism, and African-American Studies. Janessa Bailey is Leafly’s culture editor, the creator of Lumen, Leafly’s digital space highlighting Black entrepreneurs, creators, and growers in the cannabis industry. Among other topics, Janessa has written about equity, cannabis businesses, and the War on Drugs. Quotables‘Journalism, medical science, political activism, economic opportunity. That's the magic of cannabis. That's what this plant holds’ - Yoko 8:45‘Leafly is part of the connective tissue of this industry, in particular in the US’ - Anuj 17:07‘For me, social equity is a means of accountability and a means of doing something new, acknowledging the gap, first of all, and then closing it, particularly in the cannabis industry, where things simply aren't balanced’ - Janessa 18:57ResourcesLeafly’s Website: Yoko on LinkedIn: Janessa on LinkedIn: Seeds of Change: Strategies to create an equitable cannabis industry By Janessa Bailey: 
On this week's episode, we’re joined by Professor Mike Barnes, Neurologist, Director of Maple Tree Consultancy, and Chairman of The Medical Cannabis Clinicians SocietyWe explore the future of Medical Cannabis in the UK by investigating current prescribing practices, stakeholder challenges, and how the government can help develop the industry.→ View full show notes, summary, and access resources here: Professor Mike BarnesProfessor Mike Barnes is a neurologist and cannabis physician. He has worked in cannabis for 20 years, initially with GW Pharma on the first cannabis medicine - Sativex. He oversaw the first UK cannabis prescription for the child Alfie Dingley in 2018 and, after the law change in November 2018, then launched the Medical Cannabis Clinicians Society in November 2018 which now has over 250 clinical members. In 2021 he launched the Cannabis Industry Council with over 100 members across the sector. He runs a medical cannabis consultancy with Hannah Deacon who is the UK's best-known campaigner and mother of Alfie Dingley. He is the Clinical Director of the T21 project.Quotables‘[Cannabis’] medical history is actually more prominent and more robust… than its recreational history’ 09:36‘It's down to education. And I think it's Tony Blair that said, education, education, education. And that's the same with cannabis. It's absolutely essential to educate the doctors first, educate politicians after say second, but it's mainly the conservatism of medical professionals holding it back now’ 27:45ResourcesThe Medical Cannabis Clinicians Society Website: Barnes' LinkedIn: Tree Consultants LinkedIn: Industry Council Website: Mike Barnes’ Website:
On today’s show, we’re joined by Joe Dolce - Journalist, Podcaster, Author, and Founder of media training company Joe Dolce CommunicationsIn this episode, Joe shares his personal journey through the world of cannabis charting the experiences and events that informed his book, Brave New Weed, published in 2017 by HarperCollins.→ View full show notes, summary, and access resources here: Joe DolceJoe Dolce is the founder and CEO of the online education platform, with courses for healthcare practitioners, dispensary personnel and patients. He is also the author of Brave New Weed: Adventures into the Uncharted World of Cannabis, which was published to critical acclaim in 2017 and hosts the Brave New Weed podcast, which boasts an international audience of first movers, industry experts and rabble rousers with a deep interest in high-minded conversations about the plant and its many applications. Before entering the world of medical cannabis, Joe worked at the highest level of media. He is founder anc CEO of Joe Dolce Communications, one of New York City’s most highly regarded Presentation & Media Training companies, and was editor-in-chief of Details magazine. He was a contributing editor at Gourmetand has written for T: The New York Times Magazine, New York, Rolling Stone, Travel & Leisure, Departures, plus dozens of other top-tier publications. He has an MA from New York University and a BA from Northwestern University.ResourcesJoe Dolce Communications Website: Joe on LinkedIn:
In our latest episode, we welcome to the show Dr. Peter Grinspoon - author, physician, and medical cannabis educator.We explore the impact of The USA’s War on Drugs on a personal and nationwide level, as well as the impact and legacy of Peter’s father, Lester Grinspoon, who laid the intellectual framework for cannabis reform in the 1960s.→ View full show notes, summary, and access resources here: Dr. Peter GrinspoonPeter Grinspoon, M.D. is a primary care physician and cannabis specialist at Massachusetts General Hospital, an Instructor at Harvard Medical School and a certified Health and Wellness Coach. He is a board member of the advocacy group Doctors For Cannabis Regulation. He is a Contributing Editor to Harvard Health Publications as well as a TEDx Speaker. Quotables‘If we can switch people to low dose cannabinoids, we can protect so many people’s kidneys’ 16:10‘Legalisation has been such a success so far’ 22:56Resources Visit Peter’s Website: www.petergrinspoon.comJoin Peter on Twitter: @Peter_GrinspoonJoin Peter on Linkedin: 
This week, we welcome back  Dominic Day & George Kruis to the show, international Rugby players, and Co-Founders of wellness brand for athletes - fourfive CBD.We examine the changing attitudes towards cannabis in professional sport, how CBD can be used to aid recovery from sports injuries, and how regulators view the substance.→ View full show notes, summary, and access resources here: George KruisGeorge Kruis is a professional rugby player with 12 years of experience playing International and club level rugby. His love for the sport and his exceptional skills have led him to not only gain three European titles and four Premiership trophies for English Premiership club Saracens; but also achieve over 45 caps for England during 2 World Cups and a British and Irish Lions tour.About Dominic DayDom Day was a professional rugby player for 14 years. He played in the 2015 Rugby World Cup for Wales, and has over 250 top flight games to his name. His long rugby career has taken him around the globe to places including Australia and Japan, finishing his career as a proud member of the English Premiership club Saracens where he fell in love with George & CBD.Quotables‘Nutrition is a hard market to break into… you have to be a cut above the rest’ 09:50‘There is a necessity to look beyond painkillers and opioids’ 17:50ResourcesVisit fourfive CBD’s Website: Dominic on Linkedin: George on Linkedin: fourfive CBD on Instagram: 
This week, we’re joined by Sibusiso Xaba, Co-founder and CEO of Africa Cannabis Advisory Group (ACA Group) - investment, advisory, consulting, research and distribution company focusing on the African cannabis market.Together, we take a look at the current state of the African cannabis industry, including the factors and countries accelerating its development, and how the cannabis industry can help Africa to realise its economic potential.→ View full show notes, summary, and access resources here: Sibusiso XabaSibusiso Xaba is the co-founder and CEO of Africa Cannabis Advisory Group (ACA Group), a leading services provider specialised in the medical cannabis and hemp industries. Sibusiso is a seasoned finance professional, having worked at Goldman Sachs and Investec in London for over 8 years. He has extensive experience covering Africa, specialising in capital markets, debt structuring and syndication, venture capital fundraising, hedging solutions and portfolio management. Sibusiso is a Chartered Financial Analyst and holds a Business Science Degree from the University of Cape Town. He is also an Allan Gray fellow.Quotables‘Once I had realised what cannabis really represented in terms of its ability to address healthcare challenges, wellness and mental health channelnges, industrialisation, and sustainability - I was sold. I became the biggest evangelist after that‘  04:15‘Any progress is good progress’ 12:5
This week, we’re joined by Jaspreet Grewal & Sabrina Ramkellawan, founders of Knowde Group - Canadian contract research organisation and hybrid consultancy specialising in plant-based therapeutics and psychedelics.In this episode, we explore the complexities of clinical trials within the cannabis industry, including barriers to entry, the three phases of clinical trials, how to navigate the regulatory landscape, and access to funding.About Jaspreet Grewal  MBA, MSc, CCRPJaspreet Grewal is an accomplished clinician, researcher and venture partner bringing over 15 years of experience to companies focused on the Life Sciences. Throughout her career, she has held various positions with increasing responsibilities in various healthcare roles resulting in a broad skillset and robust healthcare and investment network while working in Canada, the US, the UK, the Cayman Islands, and Bermuda. Jaspreet holds a Master’s in Clinical Vision Sciences from Georgetown University, an Executive Certificate in Public Health from Harvard University and an MBA from the London School of Economics and Political Science.She is considered an expert in Healthcare and Regulatory Strategy and is a passionate advocate for building Alberta’s Life Science ecosystem. She has successfully merged her expertise in innovation, research and finance to become a dynamic leader not only nationally but internationally. Her current roles and affiliations include:Co-Founder & CEO, Knowde Group (Canada, UK and Australia)Founder & CEO, Venn Consulting (Canada)Board Director, BioAlbertaEntrepreneur in Residence, Innovate Calgary (Medical Cannabis)Global Lifesciences Consultant, Calgary Economic DevelopmentExternal Advisor to the Vi Riddell Pain & Rehabilitation Centre, Alberta Children’s Hospital  About Sabrina RamkellawanSabrina has over 20 years of clinical research experience in pharma, medical devices, natural health products and plant-based therapeutics including cannabinoids. She has held positions at or advised some top pharmaceutical, cannabis, psychedelic, and research companies. Sabrina has conducted and supported 11 cannabis research studies to date. She has previous experience leading operations at large scale global Contract Research Organisations including INC Research (now Syneos Health) as well as building successful speciality clinics. Sabrina is also passionate about education and has helped to build and currently teaches the first Certified Cannabis Educator Program at Michener Institute of Education at UHN. She has been and continues to be a speaker in the area of research and plant-based medicine. Prior to her role at Knowde Group, she was the VP of Clinical Affairs at TerrAscend Canada which is a licensed producer. In her role as Chief Operating Officer at Knowde Group, she is focused on all aspects of conducting research specialising in plant-based therapeutics and psychedelics. ResourcesJoin Sabrina on LinkedIn: Jaspreet on LinkedIn: Knowde Group on Twitter: Group’s Website: 
This week, we’re joined by Dr. Paola Cubillos - Colombian-Canadian integrative medicine physician, Medical Cannabis doctor and educator.We investigate the existing theory and evidence base behind the concept of ‘The Entourage Effect’ as coined by Professor Raphael Mechoulam, alongside the data we need to be able to validate the hypothesis.→ View full show notes, summary, and access resources here: Dr. Paola CubillosDr. Paola Cubillos is a Colombian-Canadian physician, who specializes in integrative medicine. Dr. Cubillos is a graduate from the Universidad del Rosario in Colombia, and holds a postgraduate degree from the Canadian College of Naturopathic Medicine in Canada.In addition to her clinical practice, Dr. Paola has worked in the research field, focusing on broadening the knowledge base in relation to medical cannabis evidence-based applications. She currently offers independent consulting services on research and medical affairs to medical cannabis producers.Dr. Cubillos is a recognized national and international lecturer on issues related to the evidence-based use of medical cannabis and the ethical implications of medical cannabis use and research. She is faculty of several medical cannabis diplomas offered in several universities and independent organizations in South America, such as Universidad del Rosario in Colombia, Universidad de Rosario in Argentina, Universidad Peruana Cayetano Heredia in Perú, Edcannamed in Ecuador and CAMEDA  in Argentina. Dr. Cubillos is also part of the peer review committee of the Journal of Cannabinoid Medicine. Dr. Paola has been president of the research ethics committee of the Princess Margaret Hospital in Toronto, Canada and of the research ethics committee of the Clínica Las Américas in Medellín, Colombia, and is currently a member of the Research Ethics Committee of the Canadian College of Naturopathic Medicine. Dr. Cubillos is a founding member and member of the board of directors and the scientific leader for the Pro Cannabis Colombia Association- Procannacol, and is a member of the Board of Directors of the Asociación Médica Colombiana de Cannabis Medicinal - ASOMEDCCAM.Quotables“We cannot pretend that by learning or knowing the function of the endocannabinoid system, we can expect cannabis to work in the same way” 10:20“It is the responsibility of everybody in the industry to collect as much standardised data from these products as possible so we can keep feeding [the amount of] data” 30:40
This week, we’re joined by Shahbaaz Kara-Virani, Canadian Sales Leader for dutchie - a technology platform providing e-commerce solutions for dispensaries. Shahbaaz is also a Founding Member of the Ontario Cannabis Policy Council.Our discussion explores the complex history of the Canadian medical cannabis market, the blurry line between recreational and medical cannabis use, and where the illicit market fits in.→ View full show notes, summary, and access resources here: Shahbaaz Kara-ViraniShahbaaz's mission is to help create global accessibility in the cannabis industry. He is a community builder who focuses on facilitating discussions between retailers, brands, cultivators, budtenders, and everything in between. Currently, he is the Canadian Leader at dutchie, and a founding member of the Ontario Cannabis Policy Council, helping shape cannabis legislation in Canada's most populous province. Prior to joining dutchie, Shahbaaz spent six years at Salesforce and 18 months as the Head of Sales at Lift, a key player in helping drive the early days of Canadian Cannabis. In addition, he is a co-founder/player on the Canadian Beach Soccer team, and the cannabis channel moderator for the Pavillion.Quotables‘The biggest gap in our industry is… accessing reliable information’ 19:45‘[When recreational cannabis was legalised] everyone forgot about the medicinal market’ 20:00‘There isn’t much of a difference between recreational and medical products’ 23:20ResourcesJoin Shahbaaz on LinkedIn:’s Website: dutchie on LinkedIn: dutchie on Instagram:
This week, we’re joined by Dr. Sandra Carrillo - clinical practitioner and Professor of Medical Cannabis Research & Education at The University of Panama.We discuss the use of medical cannabis, the conditions it has been proven to treat successfully, and the challenges involved in gathering evidence for its efficacy.→ View full show notes, summary, and access resources here:‘If we don’t educate doctors and healthcare practitioners about the applications of cannabinoids and the endocannabinoid system… medical cannabis will not be moving forward’ 04:50‘Through education, we can achieve the destigmatisation of the use of medical cannabis’ 05:48‘Medical cannabis is redefining the future of medicine’ 11:20‘There is a lot of potential we can unleash when we do proper research’ 32:05Resources Join Sandra on LinkedIn:’s Website: Sandra on Instagram: Sandra on Twitter: 
This week, we’re joined by Marion Mariathasan, CEO and Co-Founder of Simplifya - leading Cannabis Compliance Software provider based in the USA.We explore the importance of being legally compliant for licensed cannabis businesses, alongside how Simplifya’s acclaimed suite of compliance solutions can take the guesswork out of complex, industry-specific regulations.→ View full show notes, summary, and access resources here: Marion MariathasanMarion Mariathasan is the CEO of Simplifya, the cannabis industry’s leading regulatory and operational compliance software platform. The company’s suite of products takes the guesswork out of confusing and continually changing state and local regulations. Featuring SOPs, badge tracking, document storage, tailored reporting and employee accountability features, the company’s Custom Audit software reduces the time clients spend on compliance by up to 45 percent. Marion is also a serial entrepreneur, who has founded, invested in or been an advisor to more than a dozen start-ups. He is a regular guest speaker at events such as Denver Start-Up Week, Colorado University's program on social entrepreneurship and the United Nations Global Accelerator Initiative. Mariathasan studied Architecture and Computer Science at the University of Kansas and Computer Information Systems and holds a minor in Business Management at Emporia State University. He enjoys time with his family, cooking spicy Sri Lankan cuisine, traveling, and connecting with people.Quotables‘When you stop innovating and you stop progressing, you’re not serving yourself or your clients’ 10:00ResourcesFollow Marion on LinkedIn: Simplifya on LinkedIn:’s Website:
Download from Google Play
Download from App Store